SAN DIEGO, Mar.1, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, announced the inaugural meeting of its Scientific Advisory Board, that was held today on March 1, 2012. The Board includes representatives with distinguished backgrounds in cardiovascular medicine and research. The main focus of the Board will be to provide guidance for further clinical development and validation of FirstMark's new cardiovascular test PREvent. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant CAD. The test was recently launched, and its remarkable data is receiving a strong reception throughout cardiovascular medicine.
"We are very pleased to have access to this impressive group of innovative and nationally recognized leaders in cardiology. Each of these individuals has made substantial contributions to the field of cardiology. We look forward to the unique perspective each will bring, to help guide the quality and relevance of the test's scientific information, future clinical studies, and approaches to clinical application," says Thomas Silberg, President and CEO of GenWay Biotech.
The FirstMark Scientific Advisory Board is comprised of prominent cardiologist and research scientists including:
George A. Beller, MD, MACC
Cardiologist, University of Virginia Health System
Past President of the American College of Cardiology
Past President of the Association of University Cardiologists
Past President of the Association of Professors of Cardiology
Stephen Epstein, MD
Executive Director of the Cardiovascular Research Institute (CRI), MedStar Health Research Institute
Clinical Professor of Medicine at the Georgetown University School of Medicine
Former Chief of th
|SOURCE GenWay Biotech, Inc.|
Copyright©2010 PR Newswire.
All rights reserved